AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03450902 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo & sham acupuncture
Description: Participants will take Chinese herbal placebo which is prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive sham acupuncture, three times a week. The sham BL33, BL35, SP6, and ST36, which are 25 mm outward to BL33, BL35, SP6, and ST36, will be inserted with a depth of 2 to 3 mm.
Study NCT02904876 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Diffusion Magnetic Resonance Imaging at 6 months
Description: 2-year follow-up MRI of patients initiating treatment with Tysabri with anti-JCV antibody positive or negative. Patients enrolled will benefit from diffusion MRI at 6 months, in addition to conventional MRI.
Study NCT01407081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation Cognitive Strategy Training
Description: The strategy intervention is a 16-week program during which a trained rehabilitation coach speaks by telephone to the stroke participant and their caregiver twice a week (one approximately 45-minute 'training' call and one approximately 15-minute 'update' call). Rehabilitation discussions during the training calls will follow a detailed protocol and focus each week on the stroke education and cognitive strategy training information provided in each section of the manual provided to the participants.
Study NCT03659422 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Modified Paleolithic diet
Description: The diet eliminates legumes, grains and nightshades (as opposed to the Paleolithic diet) and is higher in vegetable and fruit intake and in omega-3 fatty rich foods.
Study NCT01989143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06480605
Description: Subjects will receive single intravenous doses of 1, 3, 10, 30, 100, 300, 600 or 800 mg of PF-06480605 solution in a dose escalation format.
Study NCT01989143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive single intravenous doses of PF-06480605 matching placebo solution in a dose escalation format.
Study NCT01989143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06480605
Description: Subjects will receive three subcutaneous doses of 30, 100, or 300 mg of PF-06480605 solution in a dose escalation format of one dose every 2 weeks (q2wk).
Study NCT01989143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive three subcutaneous doses of PF-06480605 matching placebo solution in a dose escalation format of one dose every 2 weeks (q2wk).
Study NCT01989143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06480605
Description: Subjects will receive three intravenous doses of 500 mg of PF-06480605 solution in a dose escalation format of one dose every 2 weeks (q2wk).
Study NCT01989143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive three intravenous doses of PF-06480605 matching placebo solution in a dose escalation format of one dose every 2 weeks (q2wk).
Study NCT03613805 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G5-Eversense
Description: Patients will wear sensor for 3 months, monitor blood capillary values 4 times/day. At the beginning and at the end of the period HbA1c will be measured and questionnaires will be administered
Study NCT03613805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eversense-Dexcom G5
Description: Patients will wear sensor for 3 months, monitor blood capillary values 4 times/day. At the beginning and at the end of the period HbA1c will be measured and questionnaires will be administered.~After 30-50 days of sensor implantation patients will wear also Dexcom G5 for a week to compare accuracy simultaneously
Study NCT01435863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-02L (darinaparsin for injection)
Description: Cohort 1: Darinaparsin 200 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
Study NCT01435863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-02L (darinaparsin for injection)
Description: Cohort 2: Darinaparsin 300 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
Study NCT01435863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-02L (darinaparsin for injection)
Description: Cohort 3: Darinaparsin 300 mg/m2 for 5 consecutive days every 21 days (5 days therapy, 16 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
Study NCT02475785 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FFRD and mini plates group
Description: FFRD direct loading over mini plates inserted in the mandibular symphysis
Study NCT02475785 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional FFRD
Description: FFRD inserted between maxillary and mandibular arches with the pushrods placed distal to mandibular canines
Study NCT00552084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: Fish oil supplements 4 gms will be taken daily for 24 weeks.
Study NCT00552084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplements will be taken daily for 24 weeks.
Study NCT02946918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Patients post-thyroidectomy will receive either levothyroxine in tablet form or in gelcaps. Initial dose 1.5-1.8 mcg per kg, orally and daily
Study NCT02064543 — intervention group
Intervention type: OTHER
Intervention: GAITRite
Description: mobility test assessing gait parameters
Study NCT02064543 — intervention group
Intervention type: OTHER
Intervention: ADPM
Description: mobility test assessing gait parameters
Study NCT04225988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release tacrolimus
Description: Patients will receive the extended-release formulation of tacrolimus for maintenance immunosuppression.
Study NCT04225988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate-release tacrolimus
Description: Patients will receive the immediate-release formulation of tacrolimus for maintenance immunosuppression.
Study NCT00316810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Day 0: Campath 30 mg i.v. infusion over 3-6 hours
Study NCT00316810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabbit Anti-Human Thymocyte Globulin
Description: Day O: Single shot of a polyclonal antilymphocyte preparation (ATG-Fresenius - 8 mg/kg, or IMTIX-Sangstat ATG 4 mg/kg/day).
Study NCT01525602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: PLX3397 tablets, 200mg
Study NCT01525602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel IV
Study NCT03062462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: double standard-dose clopidogrel treatment (300 mg loading dose, then 75 mg twice daily) for 5-7 days
Study NCT03062462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: half-dose ticagrelor treatment (90 mg loading dose, then 45 mg twice daily) for 5-7 days
Study NCT02651935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intellivent ASV
Description: Automated Invasive mechanical ventilation and weaning strategy
Study NCT00566579 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Double freezing technique
Study NCT00652782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rolofyline
Description: rolofyline 2.5 mg IV QD; 15 mg IV QD; 30 mg IV QD; 60 mg IV QD; 3 days
Study NCT00652782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator Placebo (unspecified)
Description: Matching placebo for rolofyline IV QD; 3 days
Study NCT03979196 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient Management
Description: Admission for a minimum of three days, administration of betamethasone, and clinical reassessment by obstetrician after three days. After the initial three day admission, further management will be at the discretion of their obstetrician who will continue their care and decide if further admissions are needed.~Weekly cervical length assessment will be performed until 28 weeks and patient readmission will be decided by their Obstetrician.~Post-intervention, women in both arms will receive the same standard of care (weekly clinic or inpatient follow-up appointments) and will be followed to delivery. Prior to delivery, participants will complete a patient Quality of Life survey and at delivery, primary and secondary outcomes will be collected.
Study NCT03979196 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient Management
Description: Avoid heavy lifting and core exercise, avoid intercourse, weekly assessment of cervical length by ultrasound and administration of betamethasone. Patients will continue with outpatient management for the remainder of their pregnancy with no admission unless the patient develops contractions, PPROM, bleeding, or the cervix is dilated to ≥1cm.~Post-intervention, women in both arms will receive the same standard of care (weekly clinic or inpatient follow-up appointments) and will be followed to delivery. Prior to delivery, participants will complete a patient Quality of Life survey and at delivery, primary and secondary outcomes will be collected.
Study NCT03280134 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: axillary lymph node dissection (ALND)
Description: If the patients had predictive nSLN+, need further axillary lymph node dissection.
Study NCT01620567 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: avocado
Description: 1 avocado/day for 6 months
Study NCT01620567 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: potato or chickpea
Description: 1 cup potatoes or chickpeas/day for 6 months
Study NCT02465840 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: custom-made dynamic hand splint
Description: custom-made dynamic splinting with more early active exercises intervention.
Study NCT02465840 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: custom-made protective hand splint
Description: Immobilization splint with gentle ROM exercises
Study NCT02465840 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: physical therapy and occupational therapy
Description: both the immobilization and Kleinert programs including physical therapy and occupational therapy for 2-3 times per week.
Study NCT02465840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy and occupational therapy
Description: both the immobilization and Kleinert programs including physical therapy and occupational therapy for 2-3 times per week.
Study NCT00486421 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2 IV weekly times 4 (days 1, 8, 15, 22)
Study NCT00486421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 1mg/kg/d PO, taper to off by 8 weeks
Study NCT01690884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: Adenosine will be infused into the brachial artery at 0.125 mg/min for 15 minutes and then at 0.5 mg/min for an additional 15 minutes,
Study NCT02874495 — intervention group
Intervention type: BEHAVIORAL
Intervention: Heart Rate Variability
Description: During MRI session, from the electrocardiographic signal. (measure of variations on R-R interval in milliseconds ms).
Study NCT01908114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Community mobilization
Study NCT01908114 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combined Oral Polio Vaccine and Inject able Polio Vaccine during SIA
Study NCT03304080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg orally daily, day 1 to day 28
Study NCT03304080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Dose I: 100 mg orally daily, day 1 to day 21, then 7 days off in a 28 day cycle (Phase 1 only) Dose II: 125 mg orally daily, day 1 to day 21, then 7 days off in a 28 day cycle
Study NCT03304080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg IV initial loading dose, followed by 6 mg/kg IV every 21 days
Study NCT03304080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840 mg IV followed by a maintenance dose of 420 mg IV every 21 days
Study NCT01690884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adenosine
Description: Adenosine will be infused into the brachial artery at 0.125 mg/min for 15 minutes and then at 0.5 mg/min for an additional 15 minutes,
Study NCT01690884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: Adenosine will be infused into the brachial artery at 0.125 mg/min for 15 minutes and then at 0.5 mg/min for an additional 15 minutes,
Study NCT04620187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ado-trastuzumab (T) emtansine (T-DM1)
Description: Intravenous infusion ever 21 days (3weeks) for 1 year (52 weeks)
Study NCT04620187 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard of Care Radiotherapy
Description: Radiotherapy to shrink or kill tumors
Study NCT04620187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Chemotherapy
Description: Intravenous injection
Study NCT02172625 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protandim Dietary Supplement
Description: This was a randomized, block design, controlling for 5-km performance and sex. Subjects were given 675 mg per day (1 pill per day) of Protandim for 90 days. Subjects ran a 5-km time trial before and after the supplementation period. Blood samples were taken pre and post supplementation.
Study NCT02172625 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: This was a randomized, block design, controlling for 5-km performance and sex. Subjects were given 675 mg per day (1 pill per day) of corn starch for 90 days. Subjects ran a 5-km time trial before and after the supplementation period. Blood samples were taken pre and post supplementation.
Study NCT04394364 — intervention group
Intervention type: DEVICE
Intervention: Bispectral index
Description: The BIS monitor will be attached to patients' forehead before anesthetized and kept until the end of the surgery
Study NCT00799643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salsalate
Description: Salsalate 3.5 g/d orally, divided dosing
Study NCT00799643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salsalate Placebo
Study NCT03081390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed meal tolerance testing
Description: An intravenous catheter is placed for serial blood draws for inflammatory markers and ancillary studies. The participant consumes a test meal, and measurements are made for 4 hours.
Study NCT03081390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin conductance & cold pressor test
Description: Skin conductance will be monitored continuously with 2 electrodes placed on the plantar surface of the foot. To induce pain, we will use the cold pressor test. Participants submerge one hand in a bath with iced water (2-4ºC) for 2 minutes. Blood pressure and heart rate are monitored every minute starting 5 minutes before the cold pressor test and for 10 minutes after the participant withdraws the hand from the bath. This testing will be performed at baseline and post-meal.
Study NCT04280744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Patient preferred song will be provided in a sedative manor (e.g., 60-80 beats per minute) using live music (singing with guitar accompaniment) by a board certified music therapist.
Study NCT02935179 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: White sweet potato diet
Description: The diet were supplied 516 kcal daily
Study NCT02935179 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: White sweet potato diet
Description: The diet were supplied 516 kcal daily
Study NCT01654120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: SC, 1.8mg,QD, six months to one year
Study NCT01654120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: SC, will be titrated during the study, 4 times a day, 1 year
Study NCT01654120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: SC, will be titrated during the study, 4 times a day, 1 year
Study NCT00520533 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric monoclonal antibody cG250
Description: First Cycle: cG250 10 mg/m² intravenous infusion, weekly for five weeks, followed by a two-week break. 1st \& 5th dose will be trace-labeled with a radioactive substance detectable on a PET scanner (124I-cG250).~Second cycle (investigator discretion): cG250 10 mg/m² intravenous infusion, weekly for four weeks followed by a two-week break. No 124I-cG250 will be used in the 2nd cycle.~Up to 2 cycles available.
Study NCT00520533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib malate
Description: First Cycle: Sunitinib 50 mg orally daily for 4 weeks (starts 8th day of 1st treatment cycle), followed by a two-week period off sunitinib.~Second cycle (investigator discretion): Sunitinib 50 mg orally daily for 4 weeks (starts on 1st day of 2nd treatment cycle), followed by a two-week period off sunitinib.~Up to 2 cycles available on-study.
Study NCT00823069 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Perlane and Perlane-L
Description: This is a split face design and each subject received both Perlane-L and Perlane. Treatments were blinded, randomized, and successive.
Study NCT04046510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ocytocin
Description: Administration of lower doses of Ocytocin in bolus and continuous infusion
Study NCT04046510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocytocin
Description: Administration of lower doses of Ocytocin in bolus and continuous infusion
Study NCT02164331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JNC guideline training
Description: Providers will receive a series of trainings on what the JNC guidelines for treating uncontrolled hypertensives are and strategies for meeting those guidelines.
Study NCT03668847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM-CHOC-PEN
Description: DM-CHOC-PEN administration by IV infusion
Study NCT01901601 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LALAK
Description: 1. A dovetail shaped cut will be made on the graft using a femtosecond laser at the eye bank. The cut depth will be proportional to the central stromal thickness of the graft. This graft will be separated from stromal bed by eye bank personnel for examination of the cut surface. High-quality graft will be replaced in preservation medium and shipped to the surgeon prior to surgery.~2. The host cornea will receive femtosecond laser cut consisting of a shallow lamellar cut with angled side cut to match the dovetail graft in a tongue-in-groove fashion. The femtosecond laser treatments will be performed under topical anesthesia in the laser suite. The femtosecond laser is an FDA-approved device for use in this indication (corneal transplantation including lamellar keratoplasty). A protective eye shield is placed over the eye. The graft will be sutured into the host bed.
Study NCT01901601 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IEK
Description: 1. A full thickness graft will be prepared at the eye bank with zigzag side cuts prepared with a femtosecond laser. The graft is separated from the rim, replaced in the preservation medium, and shipped to the surgeon prior to the surgery.~2. In the laser suite, the host cornea will be cut with the femtosecond laser with zigzag side cuts leaving a 70-100 micron bridge. A protective eye shield is placed over the eye. The graft will be sutured into the host bed.
Study NCT01901601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Retrobulbar Block or General Anesthesia
Study NCT01901601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retrobulbar Block or General Anesthesia
Study NCT01901601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: optical coherence tomography (OCT)
Description: OCT will be used to guide the depth of the graft and donor dissections. The OCT systems to be used in this study will be the RTVue (Optovue, Inc., Fremont, CA) or the Visante (Carl Zeiss Meditec, Inc., Dublin, CA). Both are FDA-approved for the mapping of corneal thickness.
Study NCT01901601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Anesthesia
Study NCT01901601 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: femtosecond laser
Description: The femtosecond laser system to be used in this study for host cornea preparation will be the Intralase FS system (iFS, AMO, Inc., Santa Ana, CA). The iFS is FDA-approved for corneal surgery including full thickness and lamellar keratoplasty. Eye banks use earlier versions of the Intralase system which are also FDA approved for this indication.